secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2023-02-07T23:59:59+00:00
Accession:  0001628280-23-002496
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive amends bylaws to update stockholder meeting procedures and director nomination requirements
--------------------------------------------------------------------------------

- Bylaws amended to eliminate requirement to re-notice adjourned meetings if time/date/place announced or in original notice.
- Removed requirement to make stockholder list available for inspection during meetings.
- Added enhanced director nomination requirements: background info, Universal Proxy Rule compliance, limit nominees to board seats.
- Nominees must provide representation on voting/compensation arrangements and compliance with laws and company policies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828023002496/0001628280-23-002496-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828023002496/aqst-20230202.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-002496

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer